Furthermore, combination treatments with bevacizumab plus FO/Se have been shown to significantly inhibit tumor PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling, and anti-apoptotic proteins in a dose-dependent manner by FO/Se in TNBC tumor-bearing mice 15. Here, MAP2K7 is linked to neoplasm.